StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35−0.01 (-2.91%)

Close on Nov 17, 2026Market cap $1.78MP/E –Yield –

RedHill Biopharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

RedHill Biopharma's price to sales ratio was 4.0× on Nov 11, 2026, against 0.2× a year earlier. Over the last 5 years it ranged from 0.0× to 12.0×, with a median of 0.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.0×+3.9
2025Dec 31, 20250.2×−0.1
2024Dec 31, 20240.2×+0.2
2023Dec 29, 20230.0×−0.0
2022Dec 30, 20220.1×−1.4
2021Dec 31, 20211.5×−36.7
2020Dec 31, 202038.1×+21.3
2019Dec 31, 201916.8×−7.7
2018Dec 31, 201824.5×–

More RedHill Biopharma figures

See a number that looks wrong?